Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats
IntroductionSulfatinib is a novel oral tyrosine kinase inhibitor (TKI) with selective inhibition of fibroblast growth factor (FGFR), colony-stimulating factor 1 receptor (CSF-1R) and vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. It has been approved for the therapy of neuroendocri...
Saved in:
| Main Authors: | Dongxin Chen, Jie Chen, Hailun Xia, Xiaohai Chen, Jinyu Hu, Guangliang Wu, Xuegu Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1498339/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bioanalytical assay for the quantification of rucaparib in rat plasma using UPLC-MS/MS: development, and validation for interaction with myricetin
by: Jingjing Nie, et al.
Published: (2025-05-01) -
Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
by: Zhe Chen, et al.
Published: (2024-11-01) -
Development and validation of a UPLC-MS/MS method for the quantification of parsaclisib and its application to pharmacokinetics and metabolic stability studies
by: Chenjian Zhou, et al.
Published: (2025-07-01) -
Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma
by: Pu Bai, et al.
Published: (2025-03-01) -
Simultaneous Determination of Multiple Acid-Suppressing Drugs by UPLC-MS/MS Method and Application for Pharmacokinetics Study
by: Li X, et al.
Published: (2025-02-01)